Jacobio Pharmaceuticals Group Co., Ltd. (HK:1167) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Jacobio Pharmaceuticals has announced the receipt of a significant upfront payment of RMB172.79 million from Allist, as part of an exclusive licensing-out agreement for two of its drugs, Glecirasib and JAB-3312. This financial boost is set to strengthen the company’s cash reserves and support the development of its drug pipeline. Investors are cautioned, however, that the success of the drugs’ development and market launch is not guaranteed.
For further insights into HK:1167 stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue